Sunshine Biopharma Seeks Shareholder Approval for Equity Plan Boost

TL;DR

**SBFMW's proxy filing reveals a significant equity plan expansion, signaling potential dilution but also executive incentive alignment; watch CEO Slilaty's outsized voting power.**

AI Summary

Sunshine Biopharma Inc. (SBFMW) is holding its 2025 Annual Meeting of Shareholders on December 11, 2025, to vote on several key proposals. Shareholders will elect five directors, ratify M&K CPAS, PLLC as the independent registered public accountant for the year ending December 31, 2025, and approve an amendment to the 2023 Equity Incentive Plan. This amendment seeks to increase the number of shares authorized for issuance under the plan to 683,000. As of October 17, 2025, there were 4,905,945 shares of common stock and 130,000 shares of Series B Preferred Stock outstanding, with each Series B share (all held by the CEO) carrying 1,000 votes. Dr. Steve N. Slilaty, CEO and Chairperson, beneficially owns 130,000 Series B Preferred shares, giving him significant voting control. Intracoastal Capital LLC holds 9.99% of common stock, while Bigger Capital Fund LP holds 6.1%. The Board of Directors met once in 2024 and took action by unanimous consent sixteen times, indicating active governance oversight.

Why It Matters

This DEF 14A filing is crucial for SBFMW investors as it outlines proposals directly impacting corporate governance and potential share dilution. The proposed increase in the 2023 Equity Incentive Plan to 683,000 shares could dilute existing shareholder value, making it a critical vote for long-term investors. For employees, a larger equity incentive pool might signal stronger retention and motivation, while customers and the broader market will watch for stability in leadership and financial oversight. In the competitive biopharma sector, a well-governed company with aligned executive incentives can be a differentiator.

Risk Assessment

Risk Level: medium — The risk level is medium due to the proposed increase in the 2023 Equity Incentive Plan to 683,000 shares, which could lead to significant shareholder dilution. Additionally, Dr. Steve N. Slilaty, the CEO, holds 130,000 shares of Series B Preferred Stock, each entitled to 1,000 votes, giving him disproportionate control over voting outcomes despite owning only 1,911 common shares directly.

Analyst Insight

Investors should carefully review the proposed amendment to the 2023 Equity Incentive Plan and consider its potential dilutive effects on their holdings. Engage with the company to understand the rationale behind the 683,000 share increase and its impact on future compensation and capital structure.

Key Numbers

• 683,000 — Shares authorized for 2023 Equity Incentive Plan (Proposed increase in shares for issuance)
• 4,905,945 — Common shares outstanding (As of October 17, 2025)
• 130,000 — Series B Preferred Stock shares outstanding (Each share has 1,000 votes, all held by CEO)
• 1,000 — Votes per Series B Preferred Stock share (Significantly amplifies CEO's voting power)
• 9.99% — Intracoastal Capital LLC common stock ownership (Significant institutional shareholder)
• 6.1% — Bigger Capital Fund LP common stock ownership (Significant institutional shareholder)
• 1 — Board meetings in 2024 (Indicates formal meetings, supplemented by unanimous consents)
• 16 — Actions by unanimous consent in 2024 (Shows active board decision-making outside formal meetings)
• 2025-12-11 — Date of Annual Meeting (Key date for shareholder votes)
• 2025-10-17 — Record Date for voting (Determines eligible shareholders for the meeting)

Key Players & Entities

• Sunshine Biopharma Inc. (company) — Registrant
• Dr. Steve N. Slilaty (person) — Chairperson of the Board of Directors and Chief Executive Officer
• M&K CPAS, PLLC (company) — Independent registered public accountant
• Intracoastal Capital LLC (company) — Principal Shareholder (9.99% common stock)
• Bigger Capital Fund LP (company) — Principal Shareholder (6.1% common stock)
• Securities and Exchange Commission (regulator) — Regulatory body
• Malek Chamoun (person) — Former president of Nora Pharma Inc., shares controlled by Dr. Slilaty
• Camille Sebaaly (person) — Director
• Dr. Abderrazzak Merzouki (person) — Director
• Dr. Andrew Keller (person) — Director

FAQ

Industry Context

Sunshine Biopharma Inc. operates in the biopharmaceutical sector, a highly competitive and research-intensive industry. Companies in this space focus on the discovery, development, and commercialization of novel therapeutics. Success often hinges on significant R&D investment, navigating complex regulatory pathways (like FDA approval), and securing funding for clinical trials and market entry.

Regulatory Implications

As a biopharmaceutical company, Sunshine Biopharma is subject to stringent regulations from bodies like the FDA. The approval process for new drugs is lengthy and costly, and any delays or failures in clinical trials can have severe financial and operational consequences. Compliance with evolving healthcare and pharmaceutical regulations is critical for market access and continued operation.

What Investors Should Do

1. Review the proposed amendment to the 2023 Equity Incentive Plan.
2. Evaluate the director nominees.
3. Consider the voting power of Series B Preferred Stock.

Key Dates

• 2025-12-11: 2025 Annual Meeting of Shareholders — Shareholders will vote on director elections, ratification of independent auditors, and an amendment to the 2023 Equity Incentive Plan.
• 2025-10-17: Record Date for 2025 Annual Meeting — Determines which shareholders are eligible to vote at the annual meeting.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about a company's annual shareholder meeting, including matters to be voted on, director nominees, and executive compensation. (This document is the primary source of information for the 2025 Annual Meeting of Shareholders.)

Equity Incentive Plan

A plan established by a company to grant stock options, restricted stock, or other equity-based awards to employees, directors, or consultants. (Shareholders are voting on an amendment to increase the number of shares authorized for issuance under the 2023 Equity Incentive Plan.)

Independent Registered Public Accountant

An external accounting firm hired by a company to audit its financial statements and provide an opinion on their fairness and accuracy. (Shareholders will vote to ratify the appointment of M&K CPAS, PLLC as the company's auditor for the fiscal year ending December 31, 2025.)

Series B Preferred Stock

A class of preferred stock with specific rights and privileges, in this case, carrying 1,000 votes per share. (The CEO holds all 130,000 shares of Series B Preferred Stock, giving him significant voting control over company decisions.)

Unanimous Consent

A method of corporate governance where decisions are made and approved by all members of the board of directors without requiring a formal meeting. (The Board of Directors took action by unanimous consent sixteen times in 2024, indicating active decision-making outside of formal meetings.)

Year-Over-Year Comparison

This filing is for the 2025 Annual Meeting, and the provided context does not include specific financial metrics or comparative data from a prior year's filing (e.g., 2024 DEF 14A or 2023 10-K). Therefore, a direct comparison of revenue growth, margin changes, or new risks versus the previous year cannot be made based on the information given.

Filing Documents

• sunshine_def14a.htm (DEF 14A) — 256KB
• 0001683168-25-007747.txt ( ) — 257KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 23 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 25 2024 ANNUAL REPORT ON FORM 10-K 25 OTHER MATTERS 25 STOCKHOLDER PROPOSALS FOR THE 2026 ANNUAL MEETING OF STOCKHOLDERS 26 i SUNSHINE BIOPHARMA INC. 333 Las Olas Way, CU4 Suite 433 Fort Lauderdale, FL 33301 October 23, 2025 To our Stockholders: On behalf of our Board of Directors, I cordially invite you to attend our 2025 Annual Meeting of Stockholders on December 11, 2025, at 10:00 a.m., Eastern Time, which shall be held online. During the meeting we will discuss the items of business described in the accompanying Notice of Annual Meeting and Proxy Statement, update you on important developments in our business and respond to any questions that you may have about us. We are furnishing proxy materials to some of our shareholders via the Internet by mailing a Notice of Internet Availability of Proxy Materials instead of mailing or emailing copies of those materials. The Notice of Internet Availability of Proxy Materials directs shareholders to a website where they can access our proxy materials, including our proxy statement and our annual report, and view instructions on how to vote via the Internet, mobile device, or by telephone. If you received a Notice of Internet Availability of Proxy Materials and would prefer to receive a paper copy of our proxy materials, please follow the instructions included in the Notice of Internet Availability of Proxy Materials. I look forward to your participation at the meeting. Yours truly, Dr. Steve N. Slilaty Chairperson of the Board of Directors 1 SUNSHINE BIOPHARMA INC. 333 Las Olas Way, CU4 Suite 433 Fort Lauderdale, FL 33301 NOTICE OF 2025 ANNUAL MEETING OF SHAREHOLDERS TO BE HELD THURSDAY, DECEMBER 11, 2025 Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held Thursday, December 11, 2025 The Notice of 2025 Annual Meeting, Proxy Statement and our Annual Rep

View Full Filing

View this DEF 14A filing on SEC EDGAR